Diagnostic_JJ Techniques_NP To_TO Detect_NP Cryptic_NP Leishmaniasis_NP in_IN Dogs_NP This_DT study_NN of_IN several_JJ techniques_NNS for_IN detecting_VBG cryptic_JJ leishmaniasis_NN in_IN dogs_NNS from_IN areas_NNS in_IN Spain_NP where_WRB Leishmania_NP infantum_NN is_VBZ highly_RB endemic_JJ concludes_VBZ that_IN immunological_JJ techniques_NNS (_( enzyme-linked_JJ immunosorbent_JJ assay_NN ,_, immunofluorescence_NN antibody_NN test_NN ,_, Western_JJ blotting_VBG ,_, delayed-type_NN hypersensitivity_NN reaction_NN ,_, and_CC in_IN vitro_NN lymphocyte_NN proliferation_NN assay_NN )_) do_VBP not_RB clearly_RB differentiate_VB between_IN noninfected_JJ and_CC infected_JJ asymptomatic_JJ dogs_NNS and_CC that_DT culture_NN and_CC PCR_NP are_VBP more_RBR reliable_JJ diagnostic_JJ tools_NNS ._SENT Seroepidemiological_JJ studies_NNS of_IN canine_JJ leishmaniasis_NN have_VBP revealed_VBN a_DT large_JJ number_NN of_IN asymptomatic_JJ seropositive_JJ animals_NNS ._SENT Moreover_RB ,_, in_IN areas_NNS where_WRB leishmaniasis_NN is_VBZ highly_RB endemic_JJ ,_, a_DT high_JJ proportion_NN of_IN apparently_RB healthy_JJ animals_NNS show_VBP low_JJ levels_NNS of_IN anti-Leishmania_NN antibodies_NNS ._SENT Serological_JJ follow-up_NN of_IN these_DT animals_NNS has_VBZ revealed_VBN that_IN some_DT of_IN them_PP are_VBP in_IN the_DT prepatent_JJ infection_NN period_NN ,_, which_WDT will_MD lead_VB to_TO increased_VBN antibody_NN titers_NNS in_IN subsequent_JJ blood_NN extractions_NNS ._SENT Others_NNS have_VBP regressive_JJ forms_NNS of_IN the_DT disease_NN ,_, and_CC their_PP$ antibody_NN levels_NNS will_MD decrease_VB in_IN the_DT following_VBG months_NNS or_CC years_NNS ;_: still_RB others_NNS maintain_VBP low_JJ levels_NNS of_IN antibodies_NNS without_IN developing_VBG the_DT disease_NN for_IN many_JJ years_NNS ._SENT However_RB ,_, the_DT total_JJ number_NN of_IN infected_JJ animals_NNS is_VBZ unknown_JJ ._SENT The_DT detection_NN of_IN the_DT extent_NN of_IN the_DT infection_NN ,_, particularly_RB among_IN asymptomatic_JJ dogs_NNS ,_, is_VBZ of_IN great_JJ importance_NN for_IN the_DT control_NN of_IN leishmaniasis_NN ._SENT Most_RBS epidemiological_JJ and_CC control_NN studies_NNS of_IN canine_JJ leishmaniasis_NN are_VBP performed_VBN by_IN serological_JJ methods_NNS ._SENT Although_IN such_JJ methods_NNS are_VBP traditionally_RB considered_VBN to_TO be_VB more_RBR sensitive_JJ than_IN parasitological_JJ techniques_NNS for_IN the_DT diagnosis_NN of_IN the_DT disease_NN ,_, they_PP underestimate_VBP the_DT prevalence_NN and_CC incidence_NN of_IN the_DT infection_NN relative_JJ to_TO those_DT estimated_VBN by_IN culture_NN and_CC PCR_NP ._SENT Indeed_RB ,_, experimentally_RB infected_VBN dogs_NNS that_WDT develop_VBP the_DT disease_NN have_VB an_DT anti-Leishmania_NN humoral_JJ immunoresponse_NN while_IN those_DT that_WDT remain_VBP asymptomatic_JJ present_NN a_DT cellular_JJ response_NN ._SENT The_DT application_NN of_IN highly_RB sensitive_JJ techniques_NNS ,_, such_JJ as_IN PCR_NP and_CC Western_NP blotting_VBG (_( WB_NP )_) ,_, as_RB well_RB as_IN the_DT optimization_NN of_IN culture_NN ,_, have_VBP improved_VBN the_DT rate_NN of_IN detection_NN of_IN leishmaniasis_NN ._SENT Here_RB ,_, we_PP compare_VBP the_DT results_NNS obtained_VBN by_IN various_JJ diagnostic_JJ methods_NNS (_( direct_JJ examination_NN ,_, culture_NN ,_, PCR_NP ,_, enzyme-linked_JJ immunosorbent_JJ assay_NN [_SYM ELISA_NP ]_SYM ,_, WB_NP ,_, delayed-type_NN hypersensitivity_NN reaction_NN [_SYM DTH_NP ]_SYM ,_, and_CC a_DT lymphocyte_NN proliferation_NN assay_NN [_SYM LPA_NP ]_SYM )_) for_IN dogs_NNS from_IN two_CD areas_NNS in_IN Spain_NP where_WRB canine_JJ leishmaniasis_NN is_VBZ endemic_JJ ,_, and_CC we_PP consider_VBP the_DT results_NNS in_IN the_DT context_NN of_IN the_DT clinical_JJ status_NN of_IN the_DT animals_NNS ._SENT The_DT study_NN was_VBD carried_VBN out_RP with_IN 72_CD animals_NNS ,_, 38_CD of_IN which_WDT were_VBD from_IN the_DT Priorat_NP ,_, an_DT area_NN in_IN northeast_JJ Spain_NP where_WRB leishmaniasis_NN is_VBZ highly_RB endemic_JJ ._SENT The_DT remaining_VBG 34_CD dogs_NNS were_VBD from_IN an_DT animal_JJ protection_NN society_NN in_IN Madrid_NP ,_, Spain_NP ._SENT Animals_NNS were_VBD selected_VBN for_IN the_DT study_NN after_IN extensive_JJ serological_JJ screening_NN for_IN anti-Leishmania-specific_JJ antibodies_NNS ,_, and_CC subjects_NNS were_VBD sometimes_RB chosen_VBN for_IN screening_VBG because_IN of_IN the_DT presence_NN of_IN sick_JJ animals_NNS in_IN the_DT kennel_NN ._SENT In_IN other_JJ cases_NNS ,_, we_PP picked_VBD asymptomatic_JJ animals_NNS with_IN specific_JJ antibodies_NNS or_CC under_IN other_JJ irregular_JJ circumstances_NNS ._SENT Thus_RB ,_, the_DT dog_NN samples_NNS were_VBD biased_VBN and_CC cannot_MD be_VB considered_VBN representative_NN of_IN the_DT whole_JJ dog_NN population_NN in_IN the_DT areas_NNS studied_VBD ._SENT Clinical_JJ symptoms_NNS and_CC lesions_NNS consistent_JJ with_IN canine_JJ leishmaniasis_NN (_( skin_NN abnormalities_NNS ,_, onychogryposis_NN ,_, weight_NN loss_NN ,_, epistaxis_NN ,_, apathy_NN ,_, ocular_JJ and_CC other_JJ lesions_NNS ,_, lymph_NN node_NN and_CC spleen_NN enlargement_NN ,_, etc._FW )_) were_VBD recorded_VBN for_IN all_DT dogs_NNS ._SENT Blood_NN was_VBD collected_VBN by_IN cephalic_JJ or_CC jugular_JJ venipuncture_NN for_IN complete_JJ blood_NN count_NN and_CC biochemical_JJ analysis_NN (_( serum_NN proteins_NNS ,_, the_DT renal_JJ markers_NNS urea_NN and_CC creatinine_NN ,_, and_CC the_DT hepatic_JJ markers_NNS aspartate_NN aminotransferase_NN and_CC alanine_NN aminotransferase_NN )_) ,_, for_IN detection_NN of_IN anti-Leishmania_NN antibodies_NNS ,_, and_CC for_IN PCR_NP and_CC LPA_NP ._SENT Popliteal_JJ lymph_NN node_NN aspirates_NNS were_VBD obtained_VBN for_IN direct_JJ examination_NN ,_, culture_NN ,_, and_CC PCR_NP ._SENT Needle_NN aspiration_NN skin_NN microbiopsy_NN was_VBD also_RB performed_VBN to_TO obtain_VB samples_NNS for_IN PCR_NP ._SENT Anti-Leishmania_NN antibodies_NNS were_VBD quantitatively_RB detected_VBN by_IN an_DT immunofluorescence_NN antibody_NN test_NN (_( IFAT_NP )_) and_CC an_DT ELISA_NP for_IN immunoglobulin_NN G2_NP (_( ELISA-IgG2_NP )_) for_IN dogs_NNS from_IN Madrid_NP and_CC by_IN ELISAs_NP for_IN protein_NN A_NP (_( ELISA-protein_NP A_NP )_) and_CC for_IN IgG2_NP for_IN dogs_NNS from_IN the_DT Priorat_NP ._SENT The_DT IFAT_NP was_VBD performed_VBN by_IN standard_JJ methods_NNS using_VBG a_DT fluorescent_JJ conjugated_JJ anti-dog_NN IgG_NP (_( heavy_JJ plus_CC light_JJ chains_NNS ;_: Jackson_NP ImmunoResearch_NP ,_, West_NP Grove_NP ,_, Pa._NP )_) at_IN a_DT 1:50_CD dilution_NN ._SENT ELISAs_NNS were_VBD performed_VBN as_IN described_VBN elsewhere_RB ._SENT Horseradish_NN peroxidase-conjugated_VBD protein_NN A_DT (_( dilution_NN ,_, 1:30,000_CD ;_: Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) and_CC anti-dog_NP IgG2_NP (_( dilutions_NNS ,_, 1:2,000_CD to_TO 1:5,000_CD ;_: Bethyl_NP Laboratories_NPS ,_, Montgomery_NP ,_, Tex._NP )_) were_VBD used_VBN as_IN second_JJ antibodies_NNS ._SENT The_DT reaction_NN results_NNS were_VBD quantified_VBN in_IN units_NNS relative_JJ to_TO those_DT of_IN a_DT positive_JJ serum_NN sample_NN that_WDT was_VBD used_VBN as_IN a_DT calibrator_NN and_CC arbitrarily_RB set_VBN at_IN 100_CD U._NP WB_NP analyses_NNS of_IN sera_NN from_IN the_DT Priorat_NP area_NN were_VBD performed_VBN at_IN the_DT Faculty_NP of_IN Pharmacy_NP ,_, Barcelona_NP ,_, Spain_NP ,_, as_RB described_VBN elsewhere_RB ._SENT Those_DT sera_NN that_WDT developed_VBD any_DT of_IN the_DT polypeptide_NN fractions_NNS of_IN 14_CD or_CC 16_CD kDa_NNS ,_, previously_RB reported_VBN as_IN 12_CD and_CC 14_CD kDa_NNS ,_, were_VBD considered_VBN positive_JJ ._SENT WB_NP analyses_NNS of_IN sera_NN from_IN the_DT Madrid_NP area_NN were_VBD performed_VBN at_IN the_DT Faculty_NP of_IN Veterinary_NP Science_NP ,_, Madrid_NP ,_, as_RB described_VBN previously_RB ._SENT The_DT sera_NN that_WDT revealed_VBD the_DT polypeptide_NN fractions_NNS of_IN 30_CD ,_, 42_CD ,_, 50_CD ,_, and_CC 57_CD kDa_NNS were_VBD considered_VBN positive_JJ ,_, as_RB reported_VBD previously_RB ._SENT The_DT correspondence_NN between_IN positive_JJ results_NNS detected_VBN by_IN each_DT method_NN has_VBZ been_VBN established_VBN (_( S._NP Mendez_NP ,_, M._NP J._NP Aisa_NP ,_, F._NP J._NP Fernandez-Perez_NP ,_, L._NP Iniesta_NP ,_, M._NP Portus_NP ,_, J._NP M._NP Alunda_NP ,_, and_CC M._NP T._NP Gomez-Munoz_NP ,_, submitted_VBN for_IN publication_NN )_) ._SENT DNA_NP for_IN PCR_NP analysis_NN was_VBD extracted_VBN with_IN a_DT PCR_NP template_NN preparation_NN kit_NN (_( Boehringer_NP Mannheim_NP ,_, Mannheim_NP ,_, Germany_NP )_) ._SENT Leishmania-specific_JJ oligonucleotide_NN primers_NNS A2_NP (_( 5'-GGGAGAAGCTCTATTGTG-3_NP '_POS )_) and_CC B1_NP (_( 5'-ACACTCAGGTCTGTAAAC-3_NP '_POS )_) were_VBD used_VBN to_TO amplify_VB a_DT 650-bp_JJ fragment_NN in_IN the_DT internal_JJ transcribed_VBN spacer_NN region_NN of_IN genomic_JJ DNA_NN ._SENT The_DT DTH_NP was_VBD performed_VBN by_IN inoculation_NN into_IN the_DT skin_NN of_IN the_DT groin_NN of_IN 0.1_CD ml_NN of_IN Leishmania_NP infantum_NN antigen_NN (_( 3_CD x_SYM 108_CD promastigotes/ml_NN )_) ,_, which_WDT was_VBD kindly_RB supplied_VBN by_IN the_DT Instituto_NP de_NP Salud_NP Carlos_NP III_NP ,_, Majadahonda_NP ,_, Spain_NP ._SENT Reactions_NNS were_VBD read_VBN after_IN 48_CD h_NN and_CC measured_VBN by_IN the_DT ballpoint_NN pen_NN method_NN ._SENT The_DT LPA_NP was_VBD performed_VBN with_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS as_RB described_VBD elsewhere_RB ._SENT Crude_JJ results_NNS are_VBP shown_VBN in_IN Table_NP ._SENT Each_DT laboratory_NN (_( Madrid_NP and_CC Barcelona_NP )_) applied_VBD its_PP$ current_JJ serological_JJ tests_NNS in_IN addition_NN to_TO the_DT ELISA-IgG2_NP ,_, which_WDT was_VBD performed_VBN in_IN both_DT laboratories_NNS with_IN the_DT same_JJ conjugates_VBZ ,_, the_DT same_JJ quantification_NN system_NN ,_, and_CC the_DT same_JJ calibrator_NN serum_NN ._SENT The_DT IgG2_NP results_NNS correlated_VBD highly_RB with_IN the_DT ELISA-protein_NP A_NP results_NNS (_( Spearman_NP 's_POS rank_JJ correlation_NN coefficient_NN ,_, 0.950_CD ;_: P_NN =_SYM 0.000_CD )_) and_CC the_DT IFAT_NP results_NNS (_( Spearman_NP 's_POS rank_JJ correlation_NN coefficient_NN ,_, 0.627_CD ;_: P_NN =_SYM 0.000_CD )_) ._SENT Therefore_RB ,_, to_TO simplify_VB this_DT discussion_NN ,_, only_RB results_NNS from_IN the_DT ELISA-IgG2_NP were_VBD included_VBN in_IN the_DT statistical_JJ analysis_NN and_CC comparison_NN of_IN techniques_NNS ._SENT In_IN contrast_NN ,_, no_DT correlation_NN was_VBD observed_VBN between_IN the_DT techniques_NNS for_IN detecting_VBG the_DT cellular_JJ immunoresponse_NN ,_, DTH_NP ,_, and_CC LPA_NP (_( Spearman_NP 's_POS rank_JJ correlation_NN coefficient_NN ,_, 0.052_CD ;_: P_NN =_SYM 0.75_CD )_) ,_, and_CC so_RB the_DT results_NNS obtained_VBN in_IN each_DT determination_NN were_VBD analyzed_VBN independently_RB ._SENT Attempts_NNS to_TO link_VB DTH_NP and_CC LPA_NP findings_NNS for_IN use_NN in_IN detecting_VBG human_JJ leishmaniasis_NN have_VBP led_VBN to_TO contradictory_JJ results_NNS ._SENT DTH_NP and_CC LPA_NP results_NNS correlated_VBN in_IN L._NP major-infected_JJ children_NNS of_IN Jericho_NP and_CC Tunisia_NP ._SENT Nevertheless_RB ,_, the_DT lymphoproliferative_JJ response_NN to_TO the_DT L._NP major_JJ antigen_NN by_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS from_IN Sudanese_JJ individuals_NNS with_IN a_DT positive_JJ leishmania_NN skin_NN test_NN and_CC no_DT history_NN of_IN cutaneous_JJ leishmaniasis_NN was_VBD similar_JJ to_TO the_DT response_NN observed_VBD in_IN Danish_JJ people_NNS with_IN no_DT reported_VBN exposure_NN to_TO Leishmania_NP parasites_NNS ._SENT TABLE_NN 1_CD |_SYM Clinical_JJ and_CC laboratory_NN findings_NNS and_CC results_NNS of_IN diagnostic_JJ methods_NNS for_IN visceral_JJ leishmaniasis_NN in_IN dogs_NNS The_DT dogs_NNS that_WDT were_VBD positive_JJ by_IN direct_JJ examination_NN ,_, culture_NN ,_, PCR_NP ,_, or_CC at_IN least_JJS two_CD immunological_JJ methods_NNS were_VBD considered_VBN probably_RB infected_JJ ._SENT Among_IN them_PP ,_, those_DT with_IN external_JJ signs_NNS of_IN leishmanial_NN disease_NN were_VBD considered_VBN to_TO be_VB symptomatic_JJ and_CC those_DT without_IN external_JJ signs_NNS of_IN disease_NN ,_, despite_IN the_DT detection_NN of_IN biochemical_JJ and_CC hematological_JJ (_( analytical_JJ )_) disorders_NNS ,_, were_VBD considered_VBN to_TO be_VB asymptomatic_JJ or_CC to_TO have_VB cryptic_JJ infections_NNS ._SENT The_DT specific_JJ IgG2_NP levels_NNS detected_VBD by_IN ELISA_NP were_VBD directly_RB related_VBN to_TO the_DT pathophysiological_JJ disorders_NNS detected_VBN during_IN the_DT physical_JJ and_CC analytical_JJ examinations_NNS ._SENT All_DT symptomatic_JJ dogs_NNS (_( 10_CD of_IN 10_CD )_) had_VBD high_JJ antibody_NN titers_NNS as_RB determined_VBN by_IN the_DT ELISA-IgG2_NP ,_, while_IN only_RB 35_CD of_IN 51_CD animals_NNS with_IN cryptic_JJ infections_NNS were_VBD positive_JJ by_IN this_DT technique_NN ._SENT FIG._NN 1_CD ._SENT |_SYM IgG2_NP expression_NN in_IN L._NP infantum_NP IgG2_NP expression_NN in_IN L._NP infantum-infected_JJ dogs_NNS is_VBZ related_VBN to_TO the_DT pathophysiology_NN ._SENT Columns_NNS indicate_VBP mean_JJ values_NNS ,_, and_CC error_NN bars_NNS indicate_VBP standard_JJ deviations_NNS ._SENT Dogs_NNS are_VBP divided_VBN into_IN cohorts_NNS as_RB follows_VBZ :_: (_( column_NN 1_CD )_) symptomatic_JJ dogs_NNS ,_, i.e._FW ,_, infected_JJ animals_NNS with_IN external_JJ signs_NNS of_IN leishmanial_NN disease_NN ;_: (_( column_NN 2_CD )_) infected_JJ dogs_NNS ,_, i.e._FW ,_, animals_NNS found_VBD positive_JJ by_IN direct_JJ examination_NN ,_, culture_NN ,_, PCR_NP ,_, or_CC at_IN least_JJS two_CD immunological_JJ techniques_NNS ;_: (_( column_NN 3_CD )_) infected_JJ asymptomatic_JJ dogs_NNS with_IN biochemical_JJ alterations_NNS ;_: (_( column_NN 4_CD )_) infected_JJ asymptomatic_JJ dogs_NNS without_IN biochemical_JJ alterations_NNS ;_: (_( column_NN 5_CD )_) noninfected_JJ dogs_NNS ._SENT n_NN ,_, number_NN of_IN dogs_NNS in_IN each_DT cohort_NN ._SENT The_DT dotted_JJ line_NN indicates_VBZ the_DT cutoff_NN separating_VBG positive_JJ and_CC negative_JJ results_NNS ._SENT The_DT positive_JJ and_CC negative_JJ results_NNS obtained_VBN with_IN the_DT techniques_NNS were_VBD compared_VBN two_CD by_IN two_CD by_IN the_DT McNemar_NP and_CC Pearson_NP tests_NNS in_IN the_DT whole_JJ dog_NN sample_NN studied_VBD ,_, in_IN animals_NNS considered_VBN to_TO be_VB infected_JJ (_( symptomatic_JJ and_CC asymptomatic_JJ animals_NNS )_) and_CC in_IN those_DT found_VBN to_TO have_VB cryptic_JJ infections_NNS ._SENT Culture_NP and_CC PCR_NP provided_VBD very_RB similar_JJ results_NNS ;_: they_PP gave_VBD the_DT same_JJ proportion_NN of_IN positives_NNS (_( McNemar_NP test_NN ,_, P_NN =_SYM 0.629_CD )_) and_CC a_DT high_JJ degree_NN of_IN association_NN (_( Pearson_NP test_NN ,_, P_NN <_SYM 0.001_CD )_) ._SENT The_DT culture_NN and_CC PCR_NP results_NNS differed_VBD for_IN 17_CD of_IN the_DT 72_CD dogs_NNS studied_VBN (_( 10_CD animals_NNS positive_JJ by_IN PCR_NP and_CC negative_JJ by_IN culture_NN and_CC 7_CD animals_NNS positive_JJ by_IN culture_NN and_CC negative_JJ by_IN PCR_NP )_) ._SENT In_IN 11_CD of_IN these_DT animals_NNS ,_, immunological_JJ techniques_NNS confirmed_VBD the_DT presence_NN of_IN parasites_NNS ._SENT In_IN three_CD cases_NNS PCR_NP was_VBD the_DT only_JJ positive_JJ test_NN ,_, and_CC in_IN two_CD cases_NNS only_RB the_DT culture_NN was_VBD positive_JJ ,_, as_RB confirmed_VBN by_IN new_JJ samples_NNS and_CC repeated_JJ analyses_NNS ._SENT TABLE_NN 2_CD |_SYM Statistical_NP analysis_NN of_IN results_NNS (_( positive/negative_NN )_) obtained_VBN by_IN various_JJ diagnostic_JJ techniques_NNS in_IN three_CD dog_NN cohorts_NNS :_: (_( i_NP )_) the_DT whole_JJ dog_NN population_NN studied_VBD ,_, (_( ii_NP )_) dogs_NNS considered_VBN to_TO be_VB infected_VBN with_IN L._NP infantum_NN ,_, and_CC (_( iii_NNS )_) asymptomatic_JJ dogs_NNS with_IN a_DT cryptic_JJ Leishmania_NP infection_NN The_DT humoral_JJ immunoresponse_NN ,_, detected_VBN as_IN L._NP infantum-specific_JJ IgG2_NP expression_NN ,_, was_VBD also_RB associated_VBN with_IN PCR_NP and_CC culture_NN results_NNS when_WRB the_DT whole_JJ dog_NN population_NN was_VBD considered_VBN (_( Pearson_NP test_NN ,_, P_NN <=_0.001) 0.05_CD )_) provided_VBD by_IN the_DT ELISA-IgG2_NP and_CC WB_NP ._SENT Moreover_RB ,_, since_IN the_DT antigen_NN treatments_NNS in_IN the_DT ELISA_NP and_CC WB_NP differed_VBD strongly_RB ,_, each_DT technique_NN identified_VBD a_DT different_JJ set_NN of_IN epitopes_NNS ,_, and_CC this_DT explains_VBZ the_DT lack_NN of_IN association_NN in_IN animal_JJ cohorts_NNS with_IN a_DT predominance_NN of_IN individuals_NNS with_IN low_JJ humoral_JJ immunoresponses_NNS ._SENT In_IN conclusion_NN ,_, visceral_JJ leishmaniasis_NN in_IN sick_JJ dogs_NNS from_IN areas_NNS of_IN endemicity_NN can_MD be_VB easily_RB diagnosed_VBN ._SENT It_PP is_VBZ characterized_VBN by_IN a_DT high_JJ humoral_JJ immunoresponse_NN that_WDT is_VBZ measurable_JJ by_IN conventional_JJ serological_JJ techniques_NNS (_( e.g._FW ,_, IFAT_NP and_CC ELISA_NP )_) and_CC a_DT high_JJ parasite_NN burden_NN that_WDT is_VBZ detectable_JJ by_IN parasitological_JJ and_CC PCR_NP methods_NNS ._SENT However_RB ,_, when_WRB we_PP deal_VBP with_IN asymptomatic_JJ animals_NNS ,_, particularly_RB in_IN epidemiological_JJ studies_NNS ,_, immunological_JJ techniques_NNS do_VBP not_RB discriminate_VB between_IN infected_JJ and_CC noninfected_JJ animals_NNS ._SENT Antibody_NN detection_NN alone_RB and_CC DTH_NP or_CC LPA_NP ,_, which_WDT are_VBP used_VBN to_TO estimate_VB the_DT infected_JJ dog_NN population_NN ,_, are_VBP not_RB suitable_JJ tools,and_NN parasitological_JJ methods_NNS and_CC PCR_NP offer_VBP more_RBR accurate_JJ results_NNS ._SENT 